(RTTNews) - CSL Ltd. (CSL, CSLLY, CSL.AX, CMXHF.PK) Monday announced that its subsidiary CSL Seqirus finalized a global collaboration and license agreement with Arcturus Therapeutics Holdings Inc (ARCT).
As per the agreement, CSL will have the exclusive license to Arcturus' next-generation mRNA technology in the fields of influenza, COVID-19 and other respiratory viral diseases. Further, CSL will get a non-exclusive license in the multi-pathogen pandemic preparedness field with the right to turn exclusive.
Arcturus Therapeutics will receive an upfront payment of $200 million as well as development and commercial milestone payments.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
